Source: Google NewsPublished on 2021-01-02
Related Articles:
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. January 4, 2021 Related ArticlesSafinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Brain Res Bull. 2020 Dec 30;: Authors: Wasan H, Singh D, Kh R Abstract The discovery and development of safinamide, an alpha-aminoamide, has been a valuable addition to the existing clinical management of Parkinson's disease (PD). The journey of safinamide dates back to the year 1983, when…
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. October 9, 2019 Related ArticlesLong-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. J Parkinsons Dis. 2019 Sep 25;: Authors: Cattaneo C, Jost WH, Bonizzoni E Abstract BACKGROUND: Parkinson's disease (PD) is characterized by a wide range of motor and non-motor symptoms. Levodopa is still the most effective drug; however, its long-term use is associated with…
- Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study. October 17, 2019 Related ArticlesSafinamide in Clinical Practice: A Spanish Multicenter Cohort Study. Brain Sci. 2019 Oct 11;9(10): Authors: Martí-Andrés G, Jiménez-Bolaños R, Arbelo-González JM, Pagonabarraga J, Duran-Herrera C, Valenti-Azcarate R, Luquin MR Abstract Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson's Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter…
- Rasagiline and safinamide as a dopamine-sparing therapy for parkinson's disease. April 10, 2019 Related ArticlesRasagiline and safinamide as a dopamine-sparing therapy for parkinson's disease. Acta Neurol Scand. 2019 Apr 08;: Authors: Avila A, Caballol N, Martín-Baranera M, Gómez-Ruiz I, Balagué-Marmaña M, Planas-Ballvé A, Cardona X Abstract OBJECTIVES: To evaluate whether the prescription of monoamine oxidase B inhibitors (MAOB-I), rasagiline and safinamide, contribute to the reduction of levodopa and/or dopamine agonists (DA) dose in…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
- Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. - Physician's Weekly January 4, 2021 Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Physician's Weekly
- The inflammasome field is heating up December 6, 2019 When a cell is sick or damaged it will send out signals alerting the immune system that something is wrong. If enough of these molecules are released, they will initate an “immune response” and this process is called inflammation. There is evidence in neurodegenerative conditions (like Parkinson’s and Alzheimer’s) that the inflammation process is involved, and inhibitors of particular…
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Safinamide (Addendum to Commission A15-18) November 17, 2017 Safinamide (Addendum to Commission A15-18) Book. 2015 11 05Authors: Institute for Quality and Efficiency in Health Care Abstract Background On 22 September 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A15-18 (Safinamide – Benefit assessment according to §35a Social Code Book (SGB) V). In…
- Onstryv Now Available to Patients with Parkinson’s Disease in Canada July 12, 2019 Patients in Canada with diagnosed Parkinson’s disease can now receive Onstryv (safinamide) to help manage their symptoms and their “off” episodes. This follows the approval of Onstryv by Health Canada in January 2019 as an add-on treatment to improve motor function in Parkinson’s patients who experience “off periods” while taking other therapies such as levodopa. The oral therapy will be…
- SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease. January 10, 2021 Related ArticlesSURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease. Brain Sci. 2021 Jan 06;11(1): Authors: Gómez-López A, Sánchez-Sánchez A, Natera-Villalba E, Ros-Castelló V, Beltrán-Corbellini Á, Fanjul-Arbós S, Pareés Moreno I, López-Sendon Moreno JL, Martínez Castrillo JC, Alonso-Canovas A Abstract BACKGROUND: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on…
- Monthly research review – October 2019 October 31, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Milestones in Parkinson’s Disease Research and Discovery April 11, 2017 “The real voyage of discovery consists not in seeking new landscapes, but in having new eyes.” Marcel Proust “The process of scientific discovery is, in effect, a continual flight from wonder.” Albert Einstein Preface: Happy birthday to James Parkinson (neurologist, geologist, scientist, activist), born April 11, 1755 and died December 21, 1824. World Parkinson’s Day April 11, 2017. Introduction to…
- Review Study Provides Update on Treatments for Parkinson’s Non-motor Symptoms March 26, 2019 Although there are now more treatment options available for non-motor symptoms in Parkinson’s disease, a lack of evidence on their effectiveness and safety means that more studies and new therapeutic strategies are needed, according to a review study. The study, “Update on Treatments for Nonmotor Symptoms of Parkinson’s Disease — An Evidence‐Based Medicine Review,” appeared in the journal Movement Disorders.…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- PD 101: Exercise, Medication, Nutrition & Lifestyle December 4, 2016 Since being diagnosed with PD in 2014, I've had the pleasure to meet individuals who have lived with Parkinson's for 10 to 20 years, and even longer. The common theme for living well with PD is regular exercise and staying active. PD may be a life sentence, but it is far from being a death sentence. Think of exercise as…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…